Navin Jacob
Stock Analyst
(n/a)
# 1,501
Out of 4,654 analysts
24
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Navin Jacob
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Neutral | $185 → $195 | $203.75 | -4.29% | 10 | Oct 9, 2024 | |
| LLY Eli Lilly | Upgrades: Buy | $363 | $834.80 | -56.52% | 8 | Sep 22, 2022 | |
| RPRX Royalty Pharma | Upgrades: Buy | $51 | $27.06 | +88.47% | 1 | Nov 9, 2020 | |
| GILD Gilead Sciences | Downgrades: Neutral | n/a | $88.98 | - | 1 | Apr 27, 2020 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $92 | $102.78 | -10.49% | 4 | Apr 13, 2020 |
AbbVie
Oct 9, 2024
Maintains: Neutral
Price Target: $185 → $195
Current: $203.75
Upside: -4.29%
Eli Lilly
Sep 22, 2022
Upgrades: Buy
Price Target: $363
Current: $834.80
Upside: -56.52%
Royalty Pharma
Nov 9, 2020
Upgrades: Buy
Price Target: $51
Current: $27.06
Upside: +88.47%
Gilead Sciences
Apr 27, 2020
Downgrades: Neutral
Price Target: n/a
Current: $88.98
Upside: -
Merck & Co.
Apr 13, 2020
Maintains: Buy
Price Target: $96 → $92
Current: $102.78
Upside: -10.49%